98-28897. Penick Corporation, Newark, New Jersey; Notice of Administrative Hearing, Summary of Comments and Objections; Notice of Hearing  

  • [Federal Register Volume 63, Number 208 (Wednesday, October 28, 1998)]
    [Notices]
    [Pages 57708-57709]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-28897]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF JUSTICE
    
    Drug Enforcement Administration
    [Docket No. 97-16]
    
    
    Penick Corporation, Newark, New Jersey; Notice of Administrative 
    Hearing, Summary of Comments and Objections; Notice of Hearing
    
        This Notice of Administrative Hearing, Summary of Comments and 
    Objections, regarding the application of Penick Corporation (Penick) 
    for registration as an importer of coca leaves, raw opium, opium poppy 
    and poppy straw concentrate, all Schedule II controlled substances, is 
    published pursuant to 21 CFR 1301.42(a). On May 12, 1997, notice was 
    published in the Federal Register \1\ stating that Penick has applied 
    to be registered as an importer of coca leaves, raw opium, opium poppy 
    and poppy straw concentrate.
    ---------------------------------------------------------------------------
    
        \1\ 62 FR 25972.
    ---------------------------------------------------------------------------
    
        On June 12, 1997, Noramco of Delaware, Inc. (Noramco), filed 
    comments and objections on the application and requested a hearing in 
    the event that the application is not denied. Mallinckrodt Chemical, 
    Inc. (Mallinckrodt), also filed comments and objections to the 
    application. Notice is hereby given that a hearing with respect to 
    Penick's application to be registered as an importer of coca leaves, 
    raw opium, opium poppy and poppy straw concentrate will be conducted 
    pursuant to the provisions of 5 U.S.C. 952(a) and 958 and 21 CFR 
    1311.42.
    
    Hearing Date: The hearing will begin at 9:30 a.m. on November 30, 1998, 
    and will be held at the Drug Enforcement Administration Headquarters, 
    600 Army Navy Drive, Hearing Room, Room E-2103, Arlington, Virginia.
    
    Notice of Appearance: Any person entitled to participate in this 
    hearing pursuant to 21 CFR 1301.42(a), and desiring to do so, may 
    participate by filing a notice of intention to participate in 
    accordance with 21 CFR 1301.54, in triplicate, with the Hearing Clerk, 
    Office of the Administrative Law Judges, Drug Enforcement 
    Administration, Washington, D.C. 20537, within 30 days of the date of 
    publication of this notice in the Federal Register. Each notice of 
    appearance must be in the form prescribed in 21 CFR 1216.48. Penick, 
    Noramco, Mallinckrodt, and DEA Office of Chief Counsel need not file a 
    notice of intention to participate.
    
    For Further Information Contact: Helen Farmer, Hearing Clerk, Drug 
    Enforcement Administration, Washington, D.C. 20537; Telephone (202) 
    307-8188.
    
    Summary of Comments and Objections
    
    Mallinckrodt's Comments
    
        Mallinckrodt states that as a result of Penick's financial 
    difficulties, which led to Penick's Chapter 11 bankruptcy petition, 
    Penick has not produced significant quantities of controlled substances 
    since 1991 and does not have the present ability to do so. Mallinckrodt 
    further asserts that Penick's bankruptcy trustee, appointed by the 
    bankruptcy court, has no experience in the controlled substance 
    business, and that the goal of Penick and its bankruptcy trustee has 
    not been to ressurect the business, but rather, to sell the business in 
    order to pay off Penick's creditors. Mallinckrodt asserts that Penick 
    has previously stated that it views its DEA registrations as its most 
    valuable assets. Mallinckrodt argues that because DEA has a policy of 
    not granting ``shelf registrations,'' i.e., registrations that the 
    applicant intends to use only in the future, Penick should not be 
    granting a DEA registration because ``[a]llowing Penick to treat its 
    DEA registrations as assets is not the proper use of [a] DEA 
    registration or the DEA registration process.''
    
    Noramco's Comments
    
        Noramco argues that Penick cannot meet the burden of demonstrating 
    that its registration is in the public interest due to a combination of 
    its financial status and its management by a court-appointed bankruptcy 
    trustee. Noramco first argues that Penick has substantial financial 
    difficulties, which has resulted in Penick producing only small amounts 
    of controlled substances since 1991 and that also caused Penick, in 
    June 1994, to file for bankruptcy under Chapter 11 of the Bankruptcy 
    Code. Normaco states that the management of Penick is now controlled by 
    a bankruptcy trustee who does not have experience in the controlled 
    substances industry. Moreover, Noramco asserts that the trustee's 
    primary function is to market Penick's assets, with Penick's DEA 
    registrations being the corporation's most significant assets. Noramco 
    claims that the bankruptcy trustee's desire to make the sale of Penick 
    more lucrative is not a lawful purpose for registration under the 
    Controlled Substances Act.
    
    [[Page 57709]]
    
    Finally, Noramco has expressed concern that Penick's poor financial 
    situation and management may increase the risk of diversion of any 
    controlled substances that it imports.
    
    The Government's Comments
    
        The Government asserts that the above-captioned proceeding is a 
    combination of a rulemaking to determine whether the Schedule II raw 
    materials coca leaves, raw opium, poppy straw, and poppy straw 
    concentrate may be imported lawfully into the United States pursuant to 
    21 U.S.C. 952(a)(1) and also an adjudication pursuant to 21 U.S.C. 
    958(a) on Penick's pending application for a DEA registration as an 
    importer of Schedule II raw materials. The Government argues that 
    because DEA does not maintain a ``contingency reserve'' of DEA 
    registrants Penick must first demonstrate that raw opium and poppy 
    straw concentrate may be imported into the United States pursuant to 21 
    U.S.C. 952(a)(1). The Government further asserts that Penick, which is 
    involved in Chapter 11 bankruptcy proceedings, must next demonstrate to 
    the Deputy Administrator that it is able to satisfy the requirements of 
    21 U.S.C. 823(a) and 958(a) and 21 CFR 1301.34(b)-(f) before the Deputy 
    Administrator will renew its DEA registration to import the above-
    listed Schedule II raw materials into the United States.
        The Government also requests that all interested parties be 
    afforded the opportunity to provide comments for such rulemaking. Due 
    to the length of time between the notice of Penick's application for 
    renewal of its DEA registration, see 62 FR 25972 (1997), and this 
    Notice of Hearing, the Government's request is granted. All interested 
    parties shall have until November 30, 1998, to file comments regarding 
    the above-mentioned rulemaking.
    
        Dated: October 22, 1998.
    Donnie R. Marshall,
    Acting Deputy Administrator, Drug Enforcement Administration.
    [FR Doc. 98-28897 Filed 10-27-98; 8:45 am]
    BILLING CODE 4410-09-M
    
    
    

Document Information

Published:
10/28/1998
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
98-28897
Dates:
The hearing will begin at 9:30 a.m. on November 30, 1998, and will be held at the Drug Enforcement Administration Headquarters, 600 Army Navy Drive, Hearing Room, Room E-2103, Arlington, Virginia.
Pages:
57708-57709 (2 pages)
Docket Numbers:
Docket No. 97-16
PDF File:
98-28897.pdf